Lifecore Biomedical to Report Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, on March 16, 2026

Lifecore Biomedical (NASDAQ: LFCR) will report fourth quarter and transition period results for the period ended December 31, 2025 on Monday, March 16, 2026 before the market opens.

Rhea-AI Summary

Lifecore Biomedical (NASDAQ: LFCR) will report fourth quarter and transition period results for the period ended December 31, 2025 on Monday, March 16, 2026 before the market opens.

A live webcast with senior management will begin at 8:30 a.m. Eastern to discuss results; a replay will be available on the company’s Investor Events & Presentations page for 30 days.

Argus Mar 10 session

-1.15% close to close Open Argus

Details

News Market Reaction – LFCR

On Mar 10, the first trading day after this news, LFCR closed 1.15% below the previous close.

Data tracked by StockTitan Argus for the Mar 10 session.

Market Context

This announcement sets the timetable for Lifecore’s next results, covering the quarter and transitio...

Analysis

This announcement sets the timetable for Lifecore’s next results, covering the quarter and transition period ending Dec 31, 2025, with a webcast on Mar 16, 2026. Prior filings showed growing revenue of $31,109 thousand and reduced losses, alongside a related-party term loan of $179,562 thousand and an adverse internal control opinion. Investors may focus on updated profitability trends, balance sheet developments, and any changes related to the registered 20,456,637 resale shares.

Key Figures

Total revenue: $31,109 thousand Prior revenue: $24,705 thousand Gross profit: $7,791 thousand +5 more

Total revenue

$31,109 thousand

Quarter ended Sep 30, 2025 (10-Q)

Prior revenue

$24,705 thousand

Prior-year quarter comparison (10-Q)

Gross profit

$7,791 thousand

Quarter ended Sep 30, 2025 (10-Q)

Operating loss

$3,067 thousand

Quarter ended Sep 30, 2025 (10-Q), improved from $11,584 thousand

Net loss

$9,991 thousand

Quarter ended Sep 30, 2025 (10-Q), versus $16,230 thousand

Cash & equivalents

$18,856 thousand

As of Sep 30, 2025 (10-Q)

Term-loan principal

$179,562 thousand

Related party term loan at 20.9% effective rate (10-Q)

Shares outstanding

37,466,352 shares

Common shares as of Oct 30, 2025 (10-Q)

Historical Context

5 past events · Latest: Mar 04

5 events

1. Mar 04

   New CDMO agreement

   24h Move

   -0.6%

   Development services agreement with Indomo for DT-001 clinical supply.

2. Feb 17

   Conference participation

   24h Move

   +1.1%

   Participation in DCAT Week 2026 to meet injectable CDMO partners.

3. Jan 16

   Inducement equity grants

   24h Move

   +0.4%

   RSUs and options granted to two newly hired employees.

4. Dec 18

   Index addition

   24h Move

   -0.6%

   Inclusion in the Nasdaq Biotechnology Index effective Dec 22, 2025.

5. Dec 17

   Major CDMO deal

   24h Move

   +9.9%

   CDMO master services agreement with new large multinational customer.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

contract development and manufacturing organization, cdmo

2 terms

contract development and manufacturing organization technical

"Lifecore, a fully integrated injectables contract development and manufacturing organization"

A contract development and manufacturing organization (CDMO) is a specialized service provider that helps other companies design, test, produce and package drugs or medical products on a hired basis. Think of it as an outsourced factory and R&D partner that lets a company scale production without building its own plants. Investors watch CDMO relationships because they affect a drug’s time-to-market, manufacturing costs, supply reliability and overall project risk, all of which influence future revenue and valuation.

cdmo technical

"organization (“CDMO”), today announced that it will report financial results"

A contract development and manufacturing organization (CDMO) is a company that provides specialized services to help develop and produce pharmaceutical products for other businesses. Think of it as a contract factory that takes a company's recipe and makes the product on their behalf. For investors, CDMOs are important because they support the growth of pharmaceutical companies and can be key partners in bringing new medicines to market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Webcast Scheduled for Monday, March 16 at 8:30 a.m. Eastern

CHASKA, Minn., March 09, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the fourth quarter and transition period ended December 31, 2025, on Monday, March 16, 2026, before the market opens. At 8:30 a.m. Eastern Time that day, members of Lifecore’s senior management team will host a webcast to discuss the results.

To listen to the live webcast, or access the archived webcast, please visit the Investor Events & Presentations page of Lifecore’s website at: https://ir.lifecore.com/events-presentations. Following the live webcast, an archived version of the webcast will be available on the company’s website for 30 days.
  
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated injectables contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.

Lifecore Biomedical, Inc. Contact Information:

Vida Strategic Partners
Stephanie Diaz (Investors & Media)
415-675-7401
sdiaz@vidasp.com

Ryan D. Lake (CFO)
Lifecore Biomedical
952-368-6244
ryan.lake@lifecore.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Lifecore (LFCR) release Q4 2025 results and when is the webcast?

Lifecore will release results before markets open on March 16, 2026, with a webcast at 8:30 a.m. Eastern. According to the company, senior management will host the webcast to discuss fourth quarter and transition period results for the period ended December 31, 2025.

How can investors join the Lifecore (LFCR) earnings webcast on March 16, 2026?

Investors can join the live webcast via Lifecore’s Investor Events & Presentations page. According to the company, the webcast link is on the investor website and will stream live at 8:30 a.m. Eastern on March 16, 2026.

Will Lifecore (LFCR) provide a replay of the March 16, 2026 webcast and for how long?

Yes. An archived version will be available for 30 days after the live event. According to the company, the replay will be posted on the Investor Events & Presentations page following the webcast for one month.

What topics will Lifecore (LFCR) management cover during the March 16, 2026 webcast?

Management will discuss fourth quarter and transition period financial results and business highlights. According to the company, senior management will present results for the period ended December 31, 2025, and respond to investor questions where applicable.

Where is the Lifecore (LFCR) webcast link located on March 16, 2026?

The webcast link is on Lifecore’s Investor Events & Presentations page at ir.lifecore.com/events-presentations. According to the company, both the live stream and the 30-day archived replay will be accessible from that page.